Systemic antibiotics

Infection Control in the Intensive Care Unit

Volumn 9788847016019, Issue , 2012, Pages 67-97

  De Gaudio, A R ^a   Rinaldi, S ^b   Adembri, C ^a  

^a CAREGGI UNIVERSITY HOSPITAL   (Italy)

^b Villa Fiorita Hospital   (Italy)

Author keywords

Concentration dependant Concentration dependant; Critically ill patient Critically ill patient; Eradication Eradication; Extended infusion Extended infusion; Inoculum effect Inoculum effect; MIC MIC; PK PD PK PD; Resistance Resistance; Sepsis Sepsis; Time dependant Time dependant

Indexed keywords

EID: 84930798666     PISSN: None     EISSN: None     Source Type: Book    
DOI: 10.1007/978-88-470-1601-9_6     Document Type: Chapter

References (51)

1. Gunderson BW, Ross GH, Ibrahim KH, Rotschafer JC (2001) What do we really know about antibiotic pharmacodynamics? Pharmacotherapy 21:302s-318s
2. Mehrota R, De Gaudio R, Palazzo M (2004) Antibiotic pharmacokinetic and pharmacodynamic considerations in critical illness. Int Care Med 30:2145-2156
3. Kollef MH (2001) Optimizing antibiotic therapy in the intensive care unit setting. Crit Care 5:189-195
4. Ambrose PG, Bhavnani SM, Rubino CM et al (2007) Pharmacokinetics-pharmacodynamics of antimicrobial therapy: it's not just for mice anymore. Clin Infect Dis 44:79-86
5. Pea F, Viale P (2009) Bench-to-bedside review: appropriate antibiotic therapy in severe sepsis and septic shock-does the dose matter? Crit Care 13:214
6. Kumar A (2009) Optimizing antimicrobial therapy in sepsis and septic shock. Crit Care Clin 25:733-751
7. Roberts JA, Lipman J (2009) Pharmacokinetic issues for antibiotics in the critically ill patient. Crit Care Med 37:840-851
8. Figueiredo Costa S (2008) Impact of antimicrobial resistance on the treatment and outcome of patients with sepsis. Shock 30:23-29
9. Lipman J, Boots R (2009) A new paradigm for treating infections: "go hard and go home". Crit Care Resusc 11:276-281
10. Lodise TP Jr, Lomaestro B, Drusano GL (2007) Piperacillin-tazobactam for Pseudomonas aeruginosa infection: clinical implications of an extended-infusion dosing strategy. Clin Infect Dis 44(3):357-363
11. Barbour A, Scaglione F, Derendorf H (2010) Class-dependent relevance of tissue distribution in the interpretation of anti-infective pharmacokinetic/pharmacodynamic indices. Int J Antimicrob Agents 35:431-438
12. Drawz SM, Bonomo RA (2010) Three decades of beta-lactamase inhibitors. Clin Microbiol Rev 23:160-201
13. Novelli A, Mini E, Mazzei T (2004) Pharmacological interactions between antibiotics and other drugs in the treatment of lower respiratory tract infections. Eur Respir Mon 28:1-26
14. Nagaoka I, Hirota S, Niyonsaba F et al (2001) Cathelicidin family of antibacterial peptides CAP18 and CAP11 inhibit the expression of TNF-alpha by blocking the binding of LPS to CD14(+) cells. J Immunol 167:3329-3338
15. Zhang L, Dhillon P, Yan H et al (2000) Interactions of bacterial cationic peptide antibiotics with outer and cytoplasmic membranes of Pseudomonas aeruginosa. Antimicrob Agents Chemother 44:3317-3321
16. Tsuzuki H, Tani T, Ueyama H, Kodama M (2001) Lipopolysaccharide: neutralization by polymyxin B shuts down the signaling pathway of nuclear factor kappa B in peripheral blood mononuclear cells, even during activation. J Surg Res 100:127-134
17. Suárez C, Gudiol F (2009) Beta-lactam antibiotics. Enferm Infecc Microbiol Clin 27(2):116-129 Article in Spanish
18. Augusto LA, Decottignies P, Synguelakis M et al (2003) Histones: A novel class of lipopolysaccharide-binding molecules. Biochemistry 42:3929-3938
19. Sullivan A, Edlund C, Nord CE (2001) Effect of antimicrobial agents on the ecological balance of human microflora. Lancet Infect Dis 1:101-114
20. Klein G (2003) Taxonomy, ecology and antibiotic resistance of enterococci from food and the gastro-intestinal tract. Int J Food Microbiol 88:123-131
21. Tannock GW (2001) Molecular assessment of intestinal microflora. Am J Clin Nutr 73(Suppl 2):410S-414S
22. Dunne C (2001) Adaptation of bacteria to the intestinal niche: probiotics and gut disorder. Inflamm Bowel Dis 7:136-145
23. Brook I (2000) The effects of amoxicillin therapy on skin flora in infants. Pediatr Dermatol 17:360-363
24. Antonelli M, Mercurio G, Di Nunno S, Recchioni G, Deangelis G (2001) De-escalation antimicrobial chemotherapy in critically ill patients: pros and cons. J Chemother 1:218-223
25. Doʇan O, Gülmez D, Hasçelik G (2010) Effect of new breakpoints proposed by Clinical and Laboratory Standards Institute in 2008 for evaluating penicillin resistance of Streptococcus pneumoniae in a Turkish University Hospital. Microb Drug Resist 16:39-41
26. Feldman C (2004) Clinical relevance of antimicrobial resistance in the management of pneumococcal community-acquired pneumonia. J Lab Clin Med 143:269-283
27. Goosen H (2003) Susceptibility of multi-drug-resistant Pseudomonas aeruginosa in intensive care units: results from the European MYSTIC study group. Clin Microbiol Infect 9:980-983
28. Kahlmeter G (2008) Breakpoints for intravenously used cephalosporins in Enterobacteriaceae-EUCAST and CLSI breakpoints. Clin Microbiol Infect 14:169-174
29. Bazan JA, Martin SI, Kaye KM (2009) Newer beta-lactam antibiotics: doripenem, ceftobiprole, ceftaroline, and cefepime. Infect Dis Clin North Am 23:983-996
30. Baughman RP (2009) The use of carbapenems in the treatment of serious infections. J Intensive Care Med 24:230-241
31. Smith CA, Baker EN (2002) Aminoglycoside antibiotic resistance by enzymatic deactivation. Curr Drug Targets Infect Disord 2:143-160
32. Viale P, Pea F (2003) What is the role of fluoroquinolones in intensive care? J Chemother 15(Suppl 3):5-10
33. Blondeau JM (2004) Fluoroquinolones: mechanism of action, classification, and development of resistance. Surv Ophthalmol 49(Suppl 2):S73-S78
34. Labro MT (2004) Macrolide antibiotics: current and future uses. Expert Opin Pharmacother 5:541-550
35. Ackermann G, Rodloff AC (2003) Drugs of the 21st century: telithromycin (HMR 3647)-The first ketolide. J Antimicrob Chemother 51:497-511
36. Malabarba A, Ciabatti R (2001) Glycopeptide derivatives. Curr Med Chem 8:1759-1773
37. Esposito S, Noviello S (2003) What is the role of glycopeptides in intensive care? J Chemother 15(Suppl 3):11-16
38. Parenti F, Schito GC, Courvalin P (2000) Teicoplanin chemistry and microbiology. J Chemother 12(Suppl 5):5-14
39. Harding I, Sorgel F (2000) Comparative pharmacokinetics of teicoplanin and vancomycin. J Chemother 12(Suppl 5):15-20
40. Lundstrom TS, Sobel JD (2000) Antibiotics for Gram-positive bacterial infections. Vancomycin, teicoplanin, quinupristin/dalfopristin, and linezolid. Infect Dis Clin North Am 14:463-474
41. Rocha JL, Kondo W, Baptista MI et al (2002) Uncommon vancomycin-induced side effects. Braz J Infect Dis 6:196-200
42. Beringer P (2001) The clinical use of colistin in patients with cystic fibrosis. Curr Opin Pulm Med 7:434-440
43. Tsubery H, Ofek I, Cohen S et al (2002) Modulation of the hydrophobic domain of polymyxin B nonapeptide: effect on outer-membrane permeabilization and lipopolysaccharide neutralization. Mol Pharmacol 62:1036-1042
44. Diekema DJ, Jones RN (2001) Oxazolidinone antibiotics. Lancet 358:1975-1982
45. Paradisi F, Corti G, Messeri D (2001) Antistaphylococcal (MSSA, MRSA, MSSE, MRSE) antibiotics. Med Clin North Am 85:1-17
46. De Gaudio AR, Di Filippo A (2003) What is the role of streptogramins in intensive care? J Chemother 15(Suppl 3):17-21
47. Hershberger E, Donabedian S, Konstantinou K, Zervos MJ (2004) Quinupristin-dalfopristin resistance in Gram-positive bacteria: mechanism of resistance and epidemiology. Clin Infect Dis 38:92-98
48. Devasahayam G, Scheld WM, Hoffman PS (2010) Newer antibacterial drugs for a new century. Expert Opin Investig Drugs 19:215-234
49. Zuckerman JM, Qamar F, Bono BR (2009) Macrolides, ketolides, and glycylcyclines: azithromycin, clarithromycin, telithromycin, tigecycline. Infect Dis Clin North Am 23:997-1026
50. Barton E, MacGowan A (2009) Future treatment options for Gram-positive infections-looking ahead. Clin Microbiol Infect 15:17-25
51. Bouza E (2009) New therapeutic choices for infections caused by methicillin-resistant Staphylococcus aureus. Clin Microbiol Infect 15:44-52